Is tacrolimus more cost-effective than high potency corticosteroids are in the treatment of atopic dermatitis?
Epstein
Ernst
E
D003362:Cost-Benefit Analysis; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000191:economics; D006801:Humans; D007166:Immunosuppressive Agents / Q000191:economics / Q000627:therapeutic use; D016559:Tacrolimus / Q000191:economics* / Q000627:therapeutic use*
D007166:Immunosuppressive Agents; D016559:Tacrolimus